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Chromosomal rearrangements between 3q21 and 3q26 elicit high-risk acute myeloid
leukemia (AML), which is often associated with elevated platelet and megakaryocyte (Mk)
numbers. The 3q rearrangements reposition a GATA2 enhancer near the EVI1 (or MECOM)
locus, which results in both EVI1 overexpression and GATA2 haploinsufficiency. However,
the mechanisms explaining how the misexpression of these 2 genes individually contribute
to leukemogenesis are unknown. To clarify the characteristics of differentiation defects
caused by EVI1 and GATA2 misexpression and to identify the cellular origin of leukemic
cells, we generated a system to monitor both inv(3) allele-driven EVI1 and Gata2 expression
in 3q-rearranged AML model mice. A cell population in which both EVI1 and Gata2 were
highly induced appeared in the bone marrows before the onset of frank leukemia. This
population had acquired serial colony-forming potential. Because hematopoietic stem/
progenitor cells (HSPCs) andMkswere enriched in this peculiar population, we analyzed the
independent EVI1 and GATA2 contributions to HSPC and Mk. We found that inv(3)-driven
EVI1 promotes accumulation of Mk-biased and myeloid-biased progenitors, Mks, and
platelets, and that Gata2 heterozygous deletion enhanced Mk-lineage skewing of EVI1-
expressing progenitors. Notably, inv(3)-directed EVI1 expression and Gata2
haploinsufficient expression cooperatively provoke a leukemia characterized by abundant
Mks and platelets. These hematological features of the mouse model phenocopy those
observed in human 3q AML. On the basis of these results, we conclude that inv(3)-driven
EVI1 expression in HSPCs and Mks collaborates with Gata2 haploinsufficiency to provoke
Mk-lineage skewing and leukemogenesis with excessive platelets, thus mimicking an
important feature of human AML.
Introduction
Chromosomal translocation and inversion between 3q21 and 3q26 [t(3;3)(q21.3;q26.2) and
inv(3)(q21.3q26.2), respectively] are observed in 1% to 2% of acute myeloid leukemias (AMLs), as
well as in myelodysplastic syndrome (MDS).1-4 Patients with AML and MDS with 3q rearrangements
have a poor prognosis.5,6 In AML cells harboring the 3q-rearranged allele, 2 genes, EVI1 (also known as
MECOM) and GATA2, are misexpressed by repositioning the GATA2 distal hematopoietic enhancer
(G2DHE) from the GATA2 locus on 3q21 close to the EVI1 locus on 3q26.7-9 Although EVI1 gene
expression is induced after acquiring G2DHE, GATA2 expression is diminished by half because of the
Submitted 16 September 2019; accepted 25 March 2020; published online 24 April
2020. DOI 10.1182/bloodadvances.2019000978.
*A.Y. and M.S. contributed equally to this work.
Data available via e-mail request to the corresponding author, Masayuki Yamamoto
(masiyamamoto@med.tohoku.ac.jp).
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
















Y user on 02 D
ecem
ber 2020
loss of G2DHE on 1 chromosome. Mechanisms underlying the
leukemogenesis provoked by EVI1 and GATA2 misexpression
remain to be clarified.
3q rearrangements are observed in several types of AML in which
AML without maturation, acute monocytic leukemia, and/or acute
megakaryocytic leukemia are frequently observed.10,11 Whereas
the blasts in patients with AML bearing 3q rearrangements are
morphologically variable, dysplastic nonblast cells, especially
megakaryocytes (Mks), are frequently observed. In addition, 7%
to 22% of the patients with 3q AML show thrombocythemia11,12;
giant and hypogranular platelets and bare Mk nuclei appear in their
peripheral blood.13 On the basis of these observations, it has been
recognized that these 3q AML and MDS are associated with
megakaryocytic abnormalities. In this regard, to clarify mecha-
nisms of leukemogenesis and related pathologies, several EVI1-
overexpressing mouse models have been established.14-17 How-
ever, none of the established mouse models recapitulates the
megakaryocytic phenotypes that are often observed in patients with
3q AML. Therefore, development of new, more accurate models is
required to address how EVI1 and GATA2 misexpression in-
dividually affect megakaryopoiesis, and to determine how either or
both contribute to the poor prognosis of patients with 3q AML.
To elucidate the mechanism of leukemogenesis associated with 3q
rearrangements, we previously generated 3q21q26-EVI1 mice
harboring a transgene that recapitulates the human inv(3)(q21q26)
allele.9 This transgene contains a 196-kbp linked bacterial artificial
chromosome (BAC) recombinant bearing the EVI1 gene and the
Gata2 enhancerG2DHE.9 In 3q21q26 mice, the human EVI1 gene
driven by G2DHE is highly expressed in hematopoietic stem and
progenitor cells (HSPCs). These mice develop leukemia in which
B2201c-Kit1Gr1– blast-like cells have leukemia-initiating capacity
and differentiate into Gr11 myeloid leukemia cells (myeloid-
differentiated leukemia), indicating that G2DHE-driven EVI1 over-
expression provokes leukemia.18
In these transgenics, the endogenous murine Gata2 alleles are
both intact, and therefore Gata2 expression did not decrease
in the 3q21q26-EVI1 mice, as it does naturally in 3q AML. To
examine the possible effects of the loss of 1 Gata2 allele on
leukemia development, we crossed the 3q21q26-EVI1 mice to
Gata2 heterozygous germ-line knockout (Gata21/gfp) mice to
recapitulate Gata2 haploinsufficiency.18 Gata2 heterozygous de-
letion hastened leukemia onset in the 3q21q26 mice.18 In these
compound mutants, B2201c-Kit1Gr1– blast-like cells failed to
differentiate into myeloid cells and developed leukemia in which
blasts had expanded (undifferentiated leukemia), showing that
Gata2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
However, approximately 30% of the 3q21q26-EVI1::Gata21/gfp
mice developed leukemia that was classified as neither the
undifferentiated nor the myeloid-differentiated type.
To probe the cellular basis for leukemogenesis associated with
3q-rearrangements, we attempted to define a discrete cell
population from which the leukemic cells originate before the
onset of frank leukemia. To do so, we generated a dual reporter
system that enabled monitoring of both inv(3) allele-derived EVI1
and endogenous Gata2 expression. This strategy revealed
a distinct candidate cell population for the origin of leukemia in
which both EVI1 and Gata2 were highly induced. Because
HSPC and Mks were enriched in this population, we analyzed the
individual and combinatorial functions of EVI1 overexpression and
Gata2 haploinsufficiency. The data show that inv(3)-driven EVI1
expression promotes the expansion of erythroid- and Mk-biased, as
well as myeloid-biased, progenitors. Reduced Gata2 expression
enhanced EVI1-driven Mk-lineage skewing. Of note, 24% of the
3q21q26-EVI1::Gata21/gfp mice developed leukemia associated
with elevated Mks and platelets, indicating that coordinated EVI1
and Gata2 misexpression provoked a leukemia that exhibits similar
features to human 3q AML cells. We conclude that inv(3)-driven
EVI1 overexpression coupled to GATA2 misexpression promotes
HSPC accumulation and Mk-lineage skewing and results in myeloid
leukemia with high platelets.
Methods
Generation of 3q21q26-tdTomato-targeting fragment
We generated a targeting fragment containing tdTomato gene and
an ampicillin-resistance (Amp) gene cassette flanked by Frt
sequences (FrtAmp). The tdTomato gene and polyA signal were
inserted between BamHI and EcoRV sites in pBluescript2-SK
vector to generate tdTomato-polyA/pBS-SK plasmid. The FrtAmp
fragment was generated by polymerase chain reaction (PCR), using
pFrtAmp plasmid19 as a template with the following primer set:
TomatoFrtAmp(f) and TomatoFrtAmp(r) (supplemental Table 1).
The FrtAmp fragment was inserted into a SalI site of tdTomato-
polyA/pBS-SK plasmid by homolog recombination, using In-Fusion
HD cloning kit (Clontech) to generate tdTomato-polyA-FrtAmp/pBS
plasmid. The 3q21q26-tdTomato targeting fragment was gener-
ated by PCR, using tdTomato-polyA-FrtAmp/pBS plasmid as
a template, with the following primer set: 3q21q26tdTomato(f) and
3q21q26tdTomato(r) (supplemental Table 1). PCR was performed
using PrimeSTAR Max DNA polymerase (Takara). PCR products
were gel-purified by Gel Extraction Kit (Qiagen).
Generation of the 3q21q26-tdTomato BAC clone
To generate the 3q21q26-tdTomato BAC clone, we modified the
3q21q26-EVI1 BAC clone that removed the Amp and neomycin-
resistance (Neo) gene, as described previously.9 We used
homologous recombination to insert the tdTomato gene into
the translation start site of the EVI1 gene in the 3q21q26-EVI1
BAC clone. BAC recombination was performed as described
previously.19,20 The EL250 strain of Escherichia coli was used
for Flp recombinase induction.19 The strain was prepared for
homologous recombination with the addition of a 15-minute
induction period in a 42°C shaking water bath before harvest.
BAC DNA and targeting constructs were transformed into the
strain by electroporation at 1.8 kV, 25 mF, and 200 W, using
a Gene Pulser (Bio-Rad). For drug selection, the antibiotics
chloramphenicol and ampicillin were added to Luria-Bertani
(LB) broth at a concentration of 25 mg/mL and 100 mg/mL,
respectively. To remove the Amp gene, Flp recombinase was
induced by supplementing arabinose to LB broth. BAC DNA
was purified using a Nucleo-bond BAC DNA preparation kit
(Macherey-Nagel). Purified BAC DNA was transformed into
DH10B strain without Flp recombinase by electroporation.
Validation of the 3q21q26-tdTomato BAC clone
We verified the homolog recombination by Southern blot analysis
(supplemental Figure 1A-B). BAC DNA was digested with restriction
enzymes (BamHI or EcoRI), electrophoresed, and transferred to
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a nylon membrane. The membrane was reacted with DNA probe
that was digoxigenin labeled, using digoxigenin DNA Labeling and
Detection Kit (Roche), subsequently reacted with alkaline
phosphatase–labeled anti-digoxigenin antibody and visualized
using nitro blue tetrazolium-5-bromo-4-chloro-3-indolyl-phosphate
(NBT-BCIP) substrate. PCR products with a primer set 59-TTC
CAGGCAGGATTCAACTC-39 and 59-TGGTGACAAATGGAA
AGCTG-39, using 3q21q26 BAC as a template, were used as
a probe (supplemental Figure 1A, orange box). Flp-mediated
recombination was confirmed by PCR and sequencing.
Generation of 3q21q26-tdTomato BAC
transgenic mice
BAC DNA was linearized by PI-SceI digestion and then purified by
phenol-chloroform extraction and ethanol precipitation. Linearized
BAC constructs were injected into BDF1 fertilized eggs. The
transgenic mice were backcrossed with C57BL/6 mice more than
8 times. Genotypes were determined by PCR with a primer set for
the transgene (59-CCTGTACGGCATGGACGAGC-39 and 59-
AGTGGCCAGATGTCAAACCA-39). Copy numbers of the trans-
genes were determined by quantitative PCR (qPCR) with a primer




3q21q26-EVI1 mice (line B)9 and Gata21/gfp mice21 were as
described previously. All animal experiments were approved by the
Animal Care Committee at Tohoku University.
Flow cytometry and cell sorting
Mononuclear cells were isolated from bone marrows, using
Histopaque-1083 (Sigma-Aldrich), following the protocol provided
by the manufacturer. The bone marrow cells were stained with sets
of antibodies, as described in supplemental Methods. Antibodies
used for flow cytometric analyses are described in supplemental
Table 2. Propidium iodide (1 mg/mL; Nacalai Tesque) was used to
remove dead cells. Analyses and cell sorting were performed using
FACSVerse and FACSAria II (BD Biosciences). Data were analyzed
using FlowJo software (BD Biosciences). To calculate absolute cell
number of each population, we counted cell numbers of bone
marrows in 2 femora and tibiae, and multiplied cell numbers and
frequencies of each cell type together.
Hematological analysis
Hematological indices were measured using an automatic blood
cell analyzer Celltac a (Nihon Kohden). Hemogram profiles were
examined by Wright-Giemsa staining. Cytospin preparations of the
cells (1 3 104 cells) were made using a Shandon Cytospin3
centrifuge (Thermo Electron Corp.).
RNA extraction and quantitative RT-PCR
Total RNA was extracted with Sepazol RNA I Super G reagent
(Nacalai Tesque) and reverse-transcribed with ReverTra Ace qPCR
RT Kit (Toyobo) according to the manufacturer’s instructions. The
resulting cDNA was used as a template for quantitative RT-PCR,
using TaqMan or SYBR Green with a QuantStudio 6 Real-time
PCR analyzer (Thermo Fisher Scientific). Primers for the other
genes are described in supplemental Table 3.
Colony-forming assays
Sorted cells were plated in methylcellulose-based medium with
recombinant mouse stem cell factor, mouse interleukin 3, human
interleukin 6, and human erythropoietin (MethoCult GF M3434,
StemCell Technologies) at a concentration of 100 cells/mL.
Colonies were scored after 7 days of incubation. For replating
experiments, the whole culture cells were pooled on day 7 and
washed twice, and 1000 cells were subjected to subsequent
culture in the same medium. Scoring for colonies and replating were
repeated every 7 days.
Disease-free survival curve
A humane endpoint of leukemia onset was defined at white blood
cell counts in the peripheral blood higher than 5 3 104/mL, and the
animals were euthanized when they reached this clinical stage. The
periods from birth to the day of leukemia onset were analyzed, and
disease-free survival curves were determined using the Kaplan-
Meier method. For survival curves of primary leukemia-developing
mice, we collected 10 mL peripheral blood from the tail vain and
counted white blood cells as well as red blood cells and platelets,
using an automatic blood cell analyzer Celltac a (Nihon Kohden).
The log-rank statistic was used to test whether the survival
distributions differed between groups.
Transplantation analysis
Sorted cells (5 3 104 cells) derived from CD45.1 homozygous or
CD45.1/CD45.2 heterozygous mice were injected into the tail vein
of sublethally (6 Gy) irradiated CD45.2 homozygous C57BL/6 mice
6 to 7 weeks old, using Gammacell 40 Exactor (MDS Nordion). We
traced the differentiation of transplanted cells by means of CD45.1
and CD45.2 marker detection.
Results
Generation of a reporter mouse that monitors inv(3)
allele-driven EVI1 expression
To identify the progenitor population in which leukemic cells
originate, we monitored concomitant EVI1 expression driven by
inv(3) allele at the same time as endogenous GATA2 expression in
the bone marrow before leukemia onset. To specifically monitor the
inv(3) allele-driven EVI1 expression profile, we generated a new
reporter transgenic mouse line, using the 3q21q26-EVI1 BAC
clone that recapitulates the genomic alterations in the 196-kb inv(3)
allele9 (Figure 1A). To this end, we introduced a tdTomato reporter
gene into the translational start site of the EVI1 gene in exon 3 of the
3q21q26-EVI1 parental BAC clone by homologous recombination
(Figure 1A; supplemental Figure 1A). We confirmed correct
recombination of tdTomato within the BAC clone by Southern
blotting and DNA sequence analysis (supplemental Figure 1A-B).
We injected the recombinant BAC into fertilized eggs and
generated 3 lines (lines A, B, and C) of BAC reporter transgenic
mice (3q21q26-tdTomato mice). Copy numbers of the integrated
transgenes were determined by qPCR, which revealed that the
mice retained between 2 and 5 copies of the transgenes
(supplemental Figure 1C). Unless noted otherwise, we used line
A, harboring 3 copies of the transgene, which faithfully recapitulated
EVI1 gene expression driven by the inv(3) allele (see next section).
To examine whether the 3q21q26-tdTomato transgene affects
hematopoiesis, we analyzed the lineage–c-Kit1Sca11 (LSK) fraction
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Figure 1. An EVI1 plus Gata2 High population has replicative potential. (A) Structures of the inv(3) allele, the 3q21q26-EVI1 BAC, and the 3q21q26-tdTomato BAC.
In the 3q21q26-tdTomato BAC, a tdTomato reporter gene was introduced at the translation start site of the EVI1 gene in the parental 3q21q26-EVI1 BAC. (B) Dual-reporter
mouse to monitor the effects of inv(3)-driven EVI1 and endogenous Gata2 expression by tdTomato and green fluorescent protein (GFP) fluorescence, respectively. (C) Repre-
sentative flow cytometric profiles of bone marrow cells recovered from Gata21/gfp::Tom or 3q21q26-EVI1::Gata21/gfp::Tom mice. (D) Relative intensities of tdTomato (left) and
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of bone marrow cells in wild-type (WT), 3q21q26-tdTomato,
3q21q26-EVI1, and 3q21q26-EVI1::3q21q26-tdTomato mice, as
accumulation of LSK cells is the most prominent signature of
3q21q26-EVI1 mice.9 We found that the percentages of LSK cells
were comparable between WT and 3q21q26-tdTomato mice and
between 3q21q26-EVI1 and 3q21q26-EVI1::3q21q26-tdTomato
mice (supplemental Figure 2A-B). In contrast, the percentage of
LSK cells was highly increased in 3q21q26-EVI1 and 3q21q26-
EVI1::3q21q26-tdTomato mice when compared with WT or
3q21q26-tdTomato mice. These results indicate that the
3q21q26-tdTomato transgene hardly affects hematopoiesis.
3q21q26-tdTomato and Gata2-GFP reporters identify
an EVI1-/Gata2-High population
To monitor the expression levels of both inv(3) allele-driven EVI1
and endogenous Gata2 simultaneously in bone marrow cells, we
crossed the 3q21q26-tdTomato mice into the heterozygousGata2-
GFP knock-in background21 (Gata21/gfp mice) and obtained
Gata21/gfp::3q21q26-tdTomato mice (hereafter Gata21/gfp::Tom
mice; Figure 1B, left). In the Gata21/gfp mice, the GFP gene is
inserted into the translation start site in the second exon of Gata2,
and therefore GFP is expressed instead of Gata2.21 To analyze the
effects of EVI1 gene overexpression, we further crossed the
Gata21/gfp::Tom mice to 3q21q26-EVI1 mice and obtained
3q21q26-EVI1::Gata21/gfp::Tom mice (Figure 1B, right).
We analyzed tdTomato and GFP fluorescence in bone marrows
of 12-week-old Gata21/gfp::Tom and 3q21q26-EVI1::
Gata21/gfp::Tom triple-mutant mice. We observed a positive
correlation between tdTomato and GFP expression in both
lines of mice before leukemia onset, indicating that inv(3)-
driven EVI1 gene expression correlates positively with endog-
enous Gata2 (Figure 1C). Moreover, we found that tdTomato
and GFP highly double-positive cells were a distinct population
in the bone marrows of both Gata21/gfp::Tom and 3q21q26-
EVI1::Gata21/gfp::Tom mice. Therefore, we fractionated these
bone marrow cells into High, Low, and Negative populations on
the basis of the intensity of tdTomato and GFP fluorescence
(Figure 1C). Intensity of tdTomato and GFP in each population
was comparable between Gata21/gfp::Tom and 3q21q26-
EVI1::Gata21/gfp::Tom mice except for the tdTomato signal in
the High population, suggesting that inv(3)-driven EVI1 did not
substantially affect tdTomato and GFP intensities (Figure 1D).
Total EVI1 (endogenous Evi1 gene plus human EVI1
transgene) and Gata2 mRNA levels in the High population
were higher than those in Low and Negative populations, both
in Gata21/gfp::Tom and 3q21q26-EVI1::Gata21/gfp::Tom mice,
indicating that tdTomato and GFP fluorescence accurately reflected
EVI1 and Gata2 gene expression, respectively (Figure 1E).
The absolute cell numbers of Negative, Low, and High populations
all increased in the 3q21q26-EVI1::Gata21/gfp::Tom mice
compared with those in the Gata21/gfp::Tom mice (Figure 1F).
Importantly, the frequency of the High population in the 3q21q26-
EVI1::Gata21/gfp::Tom mice increased significantly in comparison
with theGata21/gfp::Tom mice (Figure 1G). Based on these results,
we hypothesized that the EVI1 expression might confer
a proliferative advantage on the High population.
The High population of EVI1-expressing mice has
sequential replicative potential
To examine the replicative capacities of each progenitor cell
population, we performed colony assays on sorted High, Low, and
Negative cell populations (Figure 1C) in the presence of stem cell
factor, interleukin 3, interleukin 6, and erythropoietin. We detected
an enormous increase in colony numbers in the High population of
both Gata21/gfp::Tom and 3q21q26-EVI1::Gata21/gfp::Tom mice
(1st colonies; Figure 1H). Therefore, to ascertain whether these
cells retained serial cell division capacity, we performed replating
analyses using cells from the High population colonies. We found
that the High population of 3q21q26-EVI1::Gata21/gfp::Tom mice
had sequential colony-forming ability for at least 3 additional rounds
of replating (blue bars in second, third, and fourth colonies;
Figure 1H), whereas only a very small number of colonies were
generated after replating primary clones from the equivalent
population of Gata21/gfp::Tom mice (a green bar in second
colonies; Figure 1H). These results indicate that the EVI1-/Gata2-
High population has high colony-forming potential, and implies that
EVI1 overexpression confers serial passage ability on the High cell
population.
To examine how many High-population cells emerge in the second
to fourth colonies after replating, we performed flow cytometric
analysis of cells recovered from the High population colonies. We
found that the percentage of High cells in the 3q21q26-EVI1::
Gata21/gfp::Tom colonies maintained at approximately 70% from
the second to the fourth replated generation, whereas the
percentage of High population cells was approximately 50% in
the primary assay (Figure 1I). The reason for the increase of High
cells in the subsequent replating colonies is unknown. In contrast,
the percentage of High cells was about 30% in the primary colony
assay of the Gata21/gfp::Tom mice (Figure 1I), but these cells
essentially lost replating capacity thereafter. These results indicate
that EVI1 overexpression contributes to the proliferative capacity of
High-population cells. On the basis of these results, we hypothe-
sized that the High population of the 3q21q26-EVI1::Gata21/gfp
::Tom cells might harbor the parental preleukemic cells.
To examine the contribution of Gata2 haploinsufficiency alone to
colony-forming potential, we isolated tdTomato-high (T-High) cells
instead of the double (GFP/Tom) positive High population by using
Figure 1. (continued) GFP (right) fluorescence in High, Low, and Negative sorted populations (C). The average values for the High population in Gata21/gfp::Tom mice was
set as 1. (E) Relative mRNA levels of transgenic human plus endogenous mouse EVI1 (left) and mouse endogenous Gata2 mRNA (right). mRNA abundance was normalized to
glyceraldehyde-3-phosphate dehydrogenase mRNA. The average values for the High population in Gata21/gfp::Tom mice was set as 1. (F) Absolute number of High, Low, and
Negative cells in Gata2 haploinsufficient mice either containing or lacking the 3q21q26-EVI1 BAC. (G) Percentages of “High” population cells in the bone marrows of
Gata21/gfp::Tom and 3q21q26-EVI1::Gata21/gfp::Tom mice. (H) Colony-forming potential of High, Low, and Negative populations of Gata21/gfp::Tom and 3q21q26-EVI1::
Gata21/gfp::Tom mice. Note that the EVI1-/Gata2-High population has high colony-forming potential, and that EVI1 overexpression alone confers serial replating potential on
the High cell population. (I) Percentages of High population cells in primary and subsequent passage colonies derived from High populations of Gata21/gfp::Tom and 3q21q26-
EVI1::Gata21/gfp::Tom mice. Values represent the means 6 standard deviations (SDs). *P , .05; **P , .01 (unpaired Student t test). n.s., not significant.
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tdTomato fluorescence and side scatter from WT::Tom, Gata21/gfp
::Tom, 3q21q26-EVI1::Tom, and 3q21q26-EVI1::Gata21/gfp::Tom
mice (supplemental Figure 3A). We found that 41.3% 6 7.7% and
62.9% 6 5.7% of the T-High population were in the High
population of Gata21/gfp or 3q21q26-EVI1::Gata21/gfp mice,
respectively. The colony-formation potential and the percentage of
High cells were comparable between WT::Tom and Gata21/gfp
::Tom mice and between 3q21q26-EVI1::Tom and 3q21q26-EVI1::
Gata21/gfp::Tom mice, suggesting that any additional effects of
Gata2 heterozygous loss were undetectable in this experiment
(supplemental Figure 3B-C).
EVI1-/Gata2-High population contains HSPC
and Mks
To examine which cell types are found in the High population of
the 3q21q26-EVI1::Gata21/gfp::Tom and Gata21/gfp::Tom mice,
we next examined the expression of typical hematopoietic cell
surface markers in High and Negative/Low populations by flow
cytometry. Notably, we found that Mk-lineage cells (CD411
CD611) were highly enriched in the High population of both
Gata21/gfp::Tom and 3q21q26-EVI1::Gata21/gfp::Tom mice
(Figure 2A,F; supplemental Figure 4A). In contrast, neutrophils
(CD3–B220–Ly6G1), B cells (B2201CD191), and erythroid cells
(CD711Ter1191) were found predominantly in the Negative/Low
populations in both Gata21/gfp::Tom and 3q21q26-EVI1::
Gata21/gfp::Tom mice (Figure 2B-D,F; supplemental Figure 4B-
D). Monocytes (CD3–B220–CD1151) were also predominantly
found in the Negative/Low (especially Low) populations
(Figure 2B,F; supplemental Figure 4B). Notably, c-Kit1 HSPCs
were highly enriched in the High population in both lines of mice
(Figure 2E; supplemental Figure 4E). These results indicate that
the EVI1-/Gata2-High population contains HSPCs and Mks both
in the presence and the absence of inv(3)-driven EVI1 (Figure 2H).
These results also indicate that the inv(3) regulatory region
containing G2DHE has the potential to induce the tdTomato
reporter gene in Mk, even in the absence of inv(3)-driven EVI1
expression.
To examine which proportion of the High population represents
hematopoietic stem cells (HSCs) or multipotent progenitors
(MPPs), we analyzed LSK populations. We found that LSK cells
accounted for 8.3% 6 1.3% and 36.4% 6 8.7% of the High
population in Gata21/gfp::Tom and 3q21q26-EVI1::Gata21/gfp
::Tom mice, respectively (supplemental Figure 5A-B). We further
dissected LSK into MPP and long term-HSC (LT-HSC) fractions,
using a previously described sorting strategy.22We used a signaling
lymphocyte activation molecule–based method22 to isolate the
MPP and HSC fractions, because we found that the CD34
expression profile of 3q21q26-EVI1 mice was different from that of
WT mice (supplemental Figure 6A-B).
The percentage of LT-HSC (LSK Flt3–CD1501CD48–) in the High
population of 3q21q26-EVI1::Gata21/gfp::Tom mice was
diminished in comparison with Gata21/gfp::Tom mice. Although
the percentages of short-term HSC (ST-HSC; LSK Flt3–CD150–
CD48–) and MPP4 (LSK Flt31) were comparable in these mice, the
percentages of MPP2 (LSK Flt3–CD1501CD481) and MPP3 (LSK
Flt3–CD150–CD481) were significantly higher in 3q21q26-EVI1::
Gata21/gfp::Tom mice when compared with Gata21/gfp::Tom mice
(supplemental Figure 5A,C). These results indicate that the High
population of 3q21q26-EVI1::Gata21/gfp::Tom bone marrow cells
contains more myeloid and Mk/erythroid-primed progenitors than
the Gata21/gfp::Tom bone marrows.
Inv(3)-driven EVI1 promotes expansion of
multipotent progenitors
To elucidate the individual or combinatorial contributions of EVI1
overexpression and Gata2 haploinsufficiency to leukemogenesis,
we next analyzed the bone marrows of 12-week-old mice of 4
different genotypes: WT, Gata21/gfp (Gata2 heterozygous null
mutant), 3q21q26-EVI1 (EVI1 overexpression BAC transgenic),
and 3q21q26-EVI1::Gata21/gfp (Figure 3A). Because LSK cells
were highly enriched in the High population (Figure 2G), we first
analyzed the LSK fraction. We found that the absolute number of
LSK cells increased markedly in the 3q21q26-EVI1 and 3q21q26-
EVI1::Gata21/gfp mice when compared with the WT and
Gata21/gfp mice, indicating that inv(3)-driven expression of EVI1
enhances the expansion of the HSPC pool (Figure 3B-C).
We next fractionated LSK into separate MPP and HSC pools
(Figure 3B,D-E) and examined the frequencies of these populations
within the LSK fraction (Figure 3D), as well as the absolute numbers
of each population (Figure 3E). We found that both the frequencies
and absolute numbers of ST-HSC and MPPs were comparable
between WT and Gata21/gfp mice (Figure 3D-E); however, the
frequency of LT-HSC in Gata21/gfp mice was lower than in WT
mice, consistent with a previous report.23 Because the absolute
numbers of LT-HSC were comparable betweenWT andGata21/gfp
mice, the data suggest that loss of 1 Gata2 allele does not
substantially affect LT-HSC. These results indicate that Gata2
heterozygous deletion in the absence of inv(3)-driven EVI1 expres-
sion does not significantly affect the HSC or MPP populations.
We found that although the percentages of LT-HSC and ST-HSC
were both significantly reduced in 3q21q26-EVI1 mice when
compared with WT mice (Figure 3D), the absolute numbers of LT-
HSC and ST-HSC were comparable (Figure 3E). These data
suggest that inv(3)-driven expression of EVI1 does not induce stem-
cell expansion. Notably, both the frequencies and the absolute
numbers of erythroid-Mk-biased MPP2 and myeloid-biased MPP3
were highly elevated in 3q21q26-EVI1 mice when compared with
WT mice (Figure 3D-E). In contrast, the frequency of lymphoid-
biased MPP4 was lower in 3q21q26-EVI1 mice, whereas the
absolute numbers of MPP4 increased modestly. These results
indicate that inv(3)-driven EVI1 expression induces expansion of the
erythroid-Mk-biased MPP2 and myeloid-biased MPP3 compart-
ments, but has a negligible effect on lymphoid-biased MPP4.
We also found that the frequency of MPP2 was significantly
elevated in the 3q21q26-EVI1::Gata21/gfp mice compared with the
3q21q26-EVI1 mice (Figure 3D), indicating a significant contribu-
tion of GATA2 haploinsufficiency to the accumulation of MPP2. In
addition, the absolute number of ST-HSC increased slightly in the
3q21q26-EVI1::Gata21/gfp mice when compared with WT or
Gata21/gfp mice. These data suggest that reduced Gata2 expression
enhances MPP2 and ST-HSC expansion collaboratively with inv(3)-
elevated EVI1 expression.
Inv(3)-driven EVI1 promotes production of Mks
and platelets
Because the High population contained Mk-lineage cells in
addition to HSPC (Figure 2A), we next asked whether or not Mk
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differentiation might be affected by EVI1 and/or GATA2 mis-
expression. The data show that the absolute numbers of Mk-erythrocyte
progenitors (MEP; Figure 4A) andMk cells (CD411CD611; Figure 4B)
in the bone marrow were markedly higher in the 3q21q26-EVI1
and 3q21q26-EVI1::Gata21/gfp mice when compared with either
WT or Gata21/gfp animals. Within the Mk-lineage, the frequency of
c-Kit1 immature cells increased in both 3q21q26-EVI1 and 3q21q26-
EVI1::Gata21/gfp mice compared with WT and Gata21/gfp mice
(Figure 4C). The platelet numbers were highly increased in both
the 3q21q26-EVI1 and 3q21q26-EVI1::Gata21/gfp mice, but































































































































































































































Figure 2. EVI1 plus Gata2 High fraction contains HSPC and Mks. (A-E) Representative flow cytometric profiles of High and Low/Negative populations in Gata21/gfp
::Tom and 3q21q26-EVI1::Gata21/gfp::Tom mouse bone marrows. Red circles and boxes in each panel represent populations of Mk cells (A), monocytes and neutrophils (B),
B cells (C), erythrocytes (D), and HSPC (E). (F) Percentages of High population cells falling into cell type-specific gated fractions from Gata21/gfp::Tom (green circle) and
3q21q26-EVI1::Gata21/gfp::Tom (blue circle) mouse bone marrows; monocytes (Mono), neutrophils (Neu), B cells (B), erythroid cells (Ery), and Mks. (G) Percentages of High
populations in LK and LSK fractions from Gata21/gfp::Tom (green circle) and 3q21q26-EVI1::Gata21/gfp::Tom (blue circle) mouse bone marrows. (H) Cell populations
contained in High population (yellow background ellipse). Note that HSPC and Mk-lineage cells are both enriched in the High population. Values represent the means 6 SD.
**P , .01 (unpaired Student t test).
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Figure 3. Inv(3)-driven EVI1 expression promotes expansion of multipotent progenitors, but not LT-HSC. (A) Mouse models used for evaluation of the individual or
combinatorial contributions of EVI1 overexpression and Gata2 haploinsufficiency to leukemogenesis. Twelve-week-old mice were used for this study. (B) Representative flow
cytometric profiles of lineage-negative fractions from 12-week-old WT, Gata21/gfp, 3q21q26-EVI1, and 3q21q26-EVI1::Gata21/gfp bone marrows. Further analysis of the LSK
fraction (top) is shown in the middle panels, whereas analyses of the Flt3-low fraction in the middle panels are shown in the bottom panels. (C) Absolute numbers of LSK cells
in the bone marrows from 12-week-old WT (blue circle), Gata21/gfp (red square), 3q21q26-EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice.
(D) Percentages of LT-HSC, ST-HSC, MPP2, MPP3, and MPP4 in LSK fractions from 12-week-old WT (blue circle), Gata21/gfp (red square), 3q21q26-EVI1 (green triangle),
and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice. (E) Absolute numbers of LT-HSC, ST-HSC, MPP2, MPP3, and MPP4 in the bone marrows from 12-week-old
WT (blue circle), Gata21/gfp (red square), 3q21q26-EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice. Values represent the means 6 SD.
*P , .05; **P , .01 (1-way analysis of variance [ANOVA]).
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there was no significant difference between the 2 genotypes
(Figure 4D). These results thus support the contention that inv(3)-
driven EVI1 expression promotes Mk and platelet production
through an increase in MEP. As high platelet counts are
often observed in human leukemia cases bearing the 3q
rearrangement,11,12 these results demonstrate that 3q21q26-EVI1
and 3q21q26-EVI1::Gata21/gfp mice accurately recapitulate the
human AML phenotype.
Inv(3)-driven EVI1 impairs lymphoid differentiation
We next asked whether 3q21q26-driven EVI1 and Gata2 mis-
expression might affect other hematopoietic lineages. To this end,
we analyzed bone marrow and peripheral blood cells. Although
erythroid cell numbers (CD711Ter1191) in the bone marrow were
comparable among all 4 genotypes (Figure 4E), red blood cells in





























































































































































































































































































Figure 4. Inv(3)-driven EVI1 expression promotes Mk-lineage skewing. (A-B) Absolute numbers of MEP (A) and Mks (B) in the bone marrows of 12-week-old WT (blue
circle), Gata21/gfp (red square), 3q21q26-EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice. (C) Percentages of c-Kit1 cells in (CD411
CD611) Mk of WT (blue circle), Gata21/gfp (red square), 3q21q26-EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice. (D) Platelet (PLT)
counts in the peripheral blood of WT (blue circle), Gata21/gfp (red square), 3q21q26-EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice. Note
that inv(3)-driven EVI1 expression promotes Mk and platelet numbers through increased MEP abundance. (E) Absolute numbers of erythroid cells in the bone marrows. (F) Red
blood cell (RBC) counts in the peripheral blood of WT (blue circle), Gata21/gfp (red square), 3q21q26-EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse
triangle) mice. (G-J) Absolute numbers of neutrophils (G), monocytes (H), B cells (I), and pDCs (J) in the bone marrows of WT (blue circle), Gata21/gfp (red square), 3q21q26-
EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice. (K) Absolute numbers of thymocytes from WT (blue circle), Gata21/gfp (red square),
3q21q26-EVI1 (green triangle), and 3q21q26-EVI1::Gata21/gfp (purple reverse triangle) mice. (L) A model for lineage skewing by misexpression of EVI1 (red arrows) and
Gata2 (green circle). Values represent the means 6 SD. *P , .05; **P , .01 (1-way ANOVA).
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and 3q21q26-EVI1::Gata21/gfp mice (Figure 4F). Neutrophils (Ly6G1)
and monocytes (Ly6G–CD1151) were comparable among the 4
genotype mice (Figure 4G-H). However, we found that B lymphocytes
(B2201CD191) were significantly diminished in both the 3q21q26-
EVI1 and 3q21q26-EVI1::Gata21/gfp mice when compared with WT
or Gata21/gfp mice (Figure 4I). As the B2201CD19– flow population
has been shown to contain progenitors for plasmacytoid dendritic cells
(pDCs) in addition to B-lineage cells,24 we also examined possible
changes in pDC population (B2201CD19–CD11c1Gr11). We found
that the pDC population had also decreased significantly in the
3q21q26-EVI1 and 3q21q26-EVI1::Gata21/gfp mice (Figure 4J).
Thymocyte cellularity was also markedly reduced in both 3q21q26-
EVI1 and 3q21q26-EVI1::Gata21/gfp mice compared with WT or
Gata21/gfp mice, suggesting that EVI1 also directly or indirectly affects
T-cell development (Figure 4K). These data demonstrate that EVI1
expression driven by the 3q-rearranged allele suppresses lymphocyte
production.
As summarized in Figure 4L, we conclude, based on these results, that
EVI1 expression driven by the 3q-rearranged allele markedly promotes
hematopoietic progenitor expansion and Mk differentiation, but at the
same time, it significantly suppresses lymphoid differentiation. Although
reduction of Gata2 expression enhances the Mk bias toward MPP2
progenitors, the reduction of Gata2 expression does not significantly
increase the number of Mk cells or platelets in 3q21q26-EVI1::
Gata21/gfp mice when compared with those in 3q21q26-EVI1 mice.
These changes in Mk and platelet counts contrast starkly with the
analogous changes in leukemic cells (see next section).
Gata2 haploinsufficiency increases the incidence of
EVI1-driven leukemia with high platelet and
Mk numbers
Both 3q21q26-EVI1 and 3q21q26-EVI1::Gata21/gfp mice develop
leukemia, whereas WT and Gata21/gfp mice do not.18 Because
EVI1 andGata2 misexpression enhanced megakaryopoiesis before
leukemic onset, we next analyzed platelet counts in the peripheral
blood of leukemic 3q21q26-EVI1 and 3q21q26-EVI1::Gata21/gfp
mice. To this end, we examined hematologic indices of the
peripheral blood on a regular basis and euthanized the mice
whose white blood cell counts exceeded 5 3 104 cells/mL, which
we defined as the onset of leukemia. 3q21q26-EVI1::Gata21/gfp
mice developed leukemia earlier than 3q21q26-EVI1 mice did,
consistent with our previous analysis18 (supplemental Figure 7). At
the onset of leukemia, we measured platelet counts and Mk
numbers. We found that although most of the leukemic 3q21q26-
EVI1 mice exhibited low platelet counts when compared with the
platelet numbers in age-matched WT mice, leukemic mice in the
3q21q26-EVI1::Gata21/gfp cohort exhibited a much wider range of
platelet numbers than the 3q21q26-EVI1 group (Figure 5A). Of
note, 6 mice among the former cohort showed higher platelet
counts than WT mice.
We next analyzed the frequencies of CD411 Mk cells in the bone
marrow. Again, we found a wider range of Mk numbers in the
3q21q26-EVI1::Gata21/gfp mice than in 3q21q26-EVI1 mice
(Figure 5B). We next divided both groups of leukemic mice into 3
tiers (High-, Medium-, and Low-Mk types) and compared the
distributions of these 3 tiers in the leukemias that developed in the
presence of either 1 or 2 active Gata2 alleles. The incidence of
High-Mk leukemia increased in 3q21q26-EVI1::Gata21/gfp mice (6
of 25 mice: 24%) when compared with 3q21q26-EVI1 mice (1 of
25 mice: 4%), whereas the Medium- and Low-Mk categories were
comparable between these 2 genotypes. These results suggest
that Gata2 heterozygous deletion promotes EVI1-driven leukemia
development with high Mk and platelet numbers.
To address whether the properties of the Mks affect transformation
of EVI1-driven leukemias, we analyzed the onset of leukemia within



































































3q21q26-EVI1::Gata2 +/gfp Low (n=15)




Figure 5. Gata2 heterozygous loss increases the incidence of EVI1-driven leukemia with high platelets and Mks. (A) PLT counts in the peripheral blood of
leukemic 3q21q26-EVI1 (red circle) and 3q21q26-EVI1::Gata21/gfp (blue square) mice. An orange dotted line represents PLT levels of age-matched WT mice. (B) Percen-
tages of Mks in the bone marrows of leukemic 3q21q26-EVI1 (red circle) and 3q21q26-EVI1::Gata21/gfp (blue square) mice. (C) Kaplan-Meier survival curves of 3q21q26-
EVI1 (High-Mk type leukemia [orange dotted line], Low-Mk type leukemia [red line]), and 3q21q26-EVI1::Gata21/gfp mice (High-Mk type leukemia [turquoise line] or Low-Mk
type leukemia [blue dashed line]). *P , .05 (log-rank test).






























































































































































































Figure 6. Leukemia in the 3q21q26-EVI1::Gata21/gfp mice with high platelets has characteristics similar to those of human patients with AML harboring 3q
rearrangements. (A) Representative peripheral blood smears (Wright-Giemsa staining) from leukemic 3q21q26-EVI1::Gata21/gfp mice (High-Mk type leukemia). Note that
Blast cells (white arrowheads), myeloid cells (yellow arrowhead), micromegakaryocytes (black arrowheads), and giant platelets (arrow) are observed. (B) Representative flow
cytometric profiles of bone marrow cells from leukemic 3q21q26-EVI1::Gata21/gfp mice (High-Mk type leukemia). CD41– and CD411CD611 fractions were further subdivided
to assess granulocytic and blast cell characteristics. (C) Representative c-Kit expression profile in each fraction from leukemic 3q21q26-EVI1::Gata21/gfp mice (High-Mk type
leukemia). (D) Wright-Giemsa staining of leukemic cells from 3q21q26-EVI1::Gata21/gfp bone marrows. (E) Relative mRNA levels of EVI1 and mouse endogenous Gata2
mRNA in each population. B2201Gr1–CD41– (red), B220–Gr11CD41– (orange), B220–Gr1–CD41– (green), and B220–Gr1–CD411CD611 (blue) cells are shown. The
abundance of the mRNA was normalized to glyceraldehyde-3-phosphate dehydrogenase. Average values of B2201Gr1–CD41– population were set to 1. Values represent the
means 6 SD. *P , .05; **P , .01 (1-way ANOVA). (F) Schema for the transplantation analysis; 5 3 104 CD411B220–Gr1–, CD41–B2201Gr1–, and CD41–B220–Gr11
cells from leukemic 3q21q26-EVI1::Gata21/gfp (High-Mk type leukemia, CD45.1/CD45.2 heterozygotes or CD45.1 homozygous) mice were independently transplanted into
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(n 5 6 and 15, respectively), as well as in High- and Low-Mk
3q21q26-EVI1 mice (n 5 1 and n 5 21, respectively). We also
examined latency periods from birth to the leukemia onset
(Figure 5C). We found that the latency of High-Mk-type leukemia
in 3q21q26-EVI1::Gata21/gfp mice was comparable to that in the
Low-Mk-type leukemia, but the latency of High-Mk-type leukemia in
3q21q26-EVI1::Gata21/gfp mice was significantly shorter than that
of Low-Mk-type leukemia in 3q21q26 mice (Figure 5C). These
results imply that the Mk nature of the leukemic cells does not
correlate directly with the onset of leukemia.
3q21q26-EVI1::Gata21/gfp leukemia with elevated
platelets shows similar characteristics to patients
with AML harboring 3q rearrangements
To further characterize the High-Mk-type of leukemia developed
by the 3q21q26-EVI1::Gata21/gfp mice, we analyzed peripheral
blood smears at the onset of frank leukemia. Morphological
analysis revealed that peripheral blood cells from High-Mk
leukemic 3q21q26-EVI1::Gata21/gfp mice exhibited significant
heterogeneity (Figure 6A). We observed blast cells with large
nuclei and blue cytoplasm (white arrowhead), myeloid cells
harboring segmented nuclei (yellow arrowhead) and Mk cells
with large nuclei and light-blue unstructured cytoplasm (black
arrowhead). Morphological analysis showed that the size of Mk
cells in leukemic mice was comparable to that of blast cells and
myeloid cells, indicating that these Mks were micromegakaryo-
cytes that are smaller than normal Mk cells. We also observed
giant platelets (arrow) in the High-Mk-type leukemia. These
morphological features are similar to those found in patients with
AML harboring chromosomal rearrangements between 3q21
and 3q26.
To analyze various cell compartments from the bone marrows of the
High-Mk-type leukemia, we performed flow cytometric and mor-
phological analysis. We found that CD411CD611 Mk cells
accumulated in the leukemic bone marrow, whereas CD41– cells
also accumulated (Figure 6B). The CD41– population contained
B2201Gr1– cells, B220–Gr11 cells, and B220–Gr1– cells. To
identify the leukemic progenitor fraction within these populations,
we analyzed c-Kit expression and found that the CD41–B2201Gr1–
population also contains abundant c-Kit1 cells (Figure 6C),
consistent with the secondary leukemia observed in 3q21q26-
EVI1::Gata21/gfp mice.18
We also observed that the CD411CD611 population contained
cells with pseudopodia (Figure 6D). The CD41–B2201Gr1–
population contained blast-like cells, whereas the CD41–B220–
Gr11 cells bore myeloid-featured cells harboring segmented nuclei.
We examined EVI1 and Gata2 expression levels in the CD411
CD611B220–Gr1–, CD41–B2201Gr1–, CD41–B220–Gr11, and
CD41–B220–Gr1– cell populations (Figure 6E). The results
revealed that CD411CD611 Mk cells expressed the highest EVI1
and Gata2 levels among these populations, whereas the CD41–
B2201Gr1– cohort also expressed high levels of both EVI1 and
Gata2. In contrast, the levels of EVI1 and Gata2 were both
diminished in the CD41–B220–Gr11 myeloid cells. These expres-
sion profiles in the distinct populations of leukemic mice are similar
to those in the preleukemic mice we previously examined using
reporter genes (Figure 2). These results suggest that the CD41–
B2201Gr1– blast-like cells may supply Mk and myeloid leukemia
cells in the High-Mk-type leukemic mice.
To examine whether CD411 cells within the 3q21q26-EVI1::
Gata21/gfp bone marrow are leukemogenic, we isolated CD411
cells and transplanted them into sublethally irradiated WT mice
(Figure 6F); none of the recipient mice developed leukemia,
indicating that CD411 cells are not leukemogenic (Figure 6G).
We next isolated CD41–B2201Gr1– cells containing leukemic
blast cells from the bone marrow and transplanted the cells into
sublethally irradiated WT mice. We found that the recipients
developed leukemia containing CD411CD611 cells similar to
donor’s leukemia (Figure 6H, left panels), or leukemia occupied
by CD41–B2201Gr1– blast cells (right panels). These results
indicate that bone marrow CD41–B2201Gr1– cells from 3q21q26-
EVI1::Gata21/gfp mice are leukemogenic and that CD411CD611
cells are derived from CD41–B2201Gr1– leukemic blast cells. In
addition, these results imply that the CD41–B2201Gr1– population
contains both cells that retain the capacity to differentiate into
CD411CD611 cells and cells without that capability.
We observed that only a single 3q21q26-EVI1 mouse de-
veloped high Mk-type leukemia (Figure 5A-B). Morphological
analyses of its peripheral blood and flow cytometric analyses
of its bone marrow cells showed that the phenotype of high
Mk-type leukemia in the 3q21q26-EVI1 mouse was similar to
that observed in 3q21q26-EVI1::Gata21/gfp mice (supplemental
Figure 8A-B). On the basis of these results, we conclude that
Gata2 haploinsufficiency increases the frequency of High-Mk-
type leukemia driven by EVI1.
Discussion
Abnormal accumulation of HSPC as a consequence of differenti-
ation defects often provides an important basis for leukemogenesis.
Here, we established a new reporter mouse model that enabled us
to identify an EVI1-/Gata2High population that accumulates in mice
before leukemia onset. This population supports sequential
replicative potential in vitro, suggesting that it includes cellular
origin of leukemic cells. Because the High population contains not
only HSPCs but also Mk-lineage cells, we have investigated the
functional contributions of EVI1 andGata2 to multiple abnormal and
normal blood cell types. As summarized in Figure 7, erythroid-Mk-
biased MPP2 and myeloid-biased MPP3 are highly expanded by
inv(3)-driven EVI1 expression, whereas in contrast, inv(3)-driven
EVI1 expression does not significantly affect LT-HSC expansion.
Inv(3)-driven EVI1 expression also induces subsequent megakar-
yopoiesis (shown by the red circle in Figure 7), but haploinsufficient
Gata2 has only a modest enhancement of MPP2 or ST-HSC
cohorts (shown by the green circle). We also found that
reduced Gata2 expression increased the frequency of leukemia
in EVI1-expressing cells with a high number of platelets and Mk
among all inv(3)-driven EVI1 leukemias, thus recapitulating major
Figure 6. (continued) sublethally irradiated CD45.2 homozygous WT mice. (G) Kaplan-Meier survival curves of WT mice receiving CD411B220–Gr1–, CD41–B2201Gr1–,
and CD41–B220–Gr11 cells from leukemic 3q21q26-EVI1::Gata21/gfp mice (High-Mk type leukemia). (H) Representative flow cytometric patterns of the bone marrows of
recipient mice receiving CD41–B2201Gr1– cells.
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hematological features of patients with 3q AML. These results
indicate that inv(3)-driven EVI1 expression, coupled with GATA2
haploinsufficiency, at least partially induces Mk-lineage bias and
accumulation of MPP2 or ST-HSC, and further implies that
a component within either ST-HSC or MPP2 or a progenitor
somewhere between them may well be the cell of origin for
leukemias with elevated Mk.
In this study, we examined the characteristics of EVI1-overexpressing
cells in mice that have not yet developed leukemia by employing
a novel reporter system. To date, several mouse models of EVI1-
overexpressing AML or MDS have been established by means of bone
marrow transplantation, using cells transduced with EVI1-expressing
retroviruses or transgenic mice in which EVI1 is expressed under the
control of the Sca1 promoter.14-17 These models exhibit expansion of
hematopoietic progenitors and defective erythroid and lymphoid
lineages, which are consistent with the hematological features of the
3q21q26-EVI1 model mice we present here. However, an important
difference between the present and previous model studies is that
Mk abnormalities (including Mk accumulation and elevated platelet
numbers) have not been previously observed. In contrast, the
3q21q26-EVI1 in vivo mouse model examined here exhibits promotion
of megakaryopoiesis, as well as the expansion of other progenitors
(shown by the red circle in Figure 7). Importantly, the expression
of inv(3)-driven EVI1 is observed both in HSPC and Mk-lineage
cells. On the basis of these results, we surmise that enhanced
megakaryopoiesis in 3q21q26-EVI1model mouse may be a result
of EVI1 overexpression in megakaryocytic progenitors of the
inv(3) allele that is controlled by the G2DHE.
We also addressed megakaryocytic commitment of leukemic cells in
3q21q26-EVI1 mice. Whereas 3q21q26-EVI1 mice exhibit en-
hanced megakaryopoiesis and thrombocytosis before leukemia
onset, in most 3q21q26-EVI1 mice, the platelet numbers have
diminished by the time they develop leukemia. Notably, Gata2
heterozygous deletion promotes development of EVI1-driven leuke-
mia with increased Mk cells and platelets, supporting the notion that
GATA2 haploinsufficiency may play specific roles in the leukemo-
genesis of the high platelet-containing type leukemia. Although the
molecular mechanism or mechanisms underlying the leukemogenesis
caused by inv(3)-driven EVI1 misexpression and GATA2 haploinsuf-
ficiency are largely unknown, it is interesting to note that GATA2
upregulates Gata1 expression, a key regulator of both erythropoiesis
and megakaryopoiesis. High-level expression of GATA1 promotes
erythropoiesis, but lower-level expression of GATA1 promotes
megakaryopoiesis.25 AsGATA2 haploinsufficiency results in reduced
GATA1 expression, reduced GATA2 levels may promote megakar-
yopoiesis. In addition, it is known that GATA2 is required for
megakaryopoiesis in the absence of GATA1, and the molecular basis
for this is hypothesized to be a result of GATA2 regulation of genes
associated with cell cycle and the Mk-lineage.26On the basis of these
results, we propose that theGATA2 haploinsufficiency may confer an
increase in Mk-lineage potential in EVI1-expressing leukemic cells.
Although it is well known that 3q AML is often associated with high
numbers of Mk cells and platelets,11,12 its pathologic significance
remains unknown. In this regard, Mk cells have the potential to sustain
HSC and regulate HSC proliferation in the bone marrow.27,28 In
addition, Mk cells produce factors such as platelet-derived growth
factor that can affect the vascular niche.29 These observations imply
that high numbers of Mk and platelets may play roles in the malignant
leukemogenesis by sustaining leukemic stem cells. We provide
evidence here that the 3q21q26-EVI1::Gata21/gfp mouse represents
a significant advance in our ability to analyze the pathologic
significance of high Mk cells and platelets that is associated with
a major AML phenotype for the study of malignant leukemogenesis.
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Figure 7. A model for lineage skewing and leukemogenesis
induced by inv(3)-driven EVI1 expression and GATA2
haploinsufficiency. Inv(3)-driven EVI1 expression promotes ex-
pansion of MPP2 and MPP3, and also induces subsequent
megakaryopoiesis (all cells encompassed by the red ellipse circle).
Gata2 haploinsufficiency has a mild enhancement effect on MPP2
and ST-HSC (green circle). Based on the results that the
3q21q26-EVI1::Gata21/gfp-induced leukemias nicely recapitulate
major hematological features of patients with 3q AML with
elevated Mk and platelet numbers, it is implied that the High Mk/
platelet leukemia arises from a cell that could be ST-HSC, MPP2,
or a progenitor somewhere between these 2 (purple arrow).
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